Skip to main content
School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
  • Education
    • Degree Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory
  • School of Medicine Home
  • Department of Urology
  • News from Emory Urology
  • 2018-2021 Emory Urology News Highlights
  • 2018-2021 News Highlights

2018-2021 News Highlights

News
  • 2018-2021 News Highlights
  • 2016-2017 News Highlights
  • 2011-2015 News Highlights
  • Newsletters

Article by NCI Prostate Biomarker Center Group at Emory Receives Diverse Coverage

October 2020

An article authored by members of Emory University's NCI-funded Prostate Biomarker Center Investigator Group reports that fluorine (18F) fluciclovine positron emission tomography/computerized tomography (PET/CT) detects metastases better than conventional imaging in high-risk prostate cancer. The study was published in the October edition of the Journal of Urology, and its findings have been covered in such news sources as AUA Daily Scope and Urology Times.

The investigators consisted of first author Mehrdad Alemozaffar, MD, former Emory Urology surgeon-scientist; senior author David M. Schuster, MD, Director of the Emory Division of Nuclear Medicine and Molecular Imaging; Martin Sanda, MD, Chair of Emory Urology; and other researchers affiliated with Emory University Winship Cancer Institute.

In this clinical trial, 57 patients with high-risk prostate cancer were staged by conventional imaging, including 99mTc-methylene diphosphonate bone scanning and CT or magnetic resonance imaging (MRI). They then underwent 18F-fluciclovine (Axumin) PET/CT, followed by robotic radical prostatectomy and extended pelvic lymph node dissection.

The results led the investigators to conclude that use of 18F-fluciclovine PET/CT may more accurately stage prostate cancer, helping clinicians better plan surgery and other cancer treatment.

Read the Urology Times coverage here

Read the study abstract here

News
  • 2018-2021 News Highlights
  • 2016-2017 News Highlights
  • 2011-2015 News Highlights
  • Newsletters
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2018 Emory School of Medicine
  • Privacy Policy
  • Emergency Information